Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials
This book provides a practical introduction to unconditional approaches to planning randomised clinical trials, particularly aimed at drug development in the pharmaceutical industry. This book is aimed at providing guidance to practitioners in using average power, assurance and related concepts.
1140565014
Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials
This book provides a practical introduction to unconditional approaches to planning randomised clinical trials, particularly aimed at drug development in the pharmaceutical industry. This book is aimed at providing guidance to practitioners in using average power, assurance and related concepts.
59.99 Pre Order
Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials

Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials

by Andrew P. Grieve
Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials

Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials

by Andrew P. Grieve

Paperback

$59.99 
  • SHIP THIS ITEM
    Qualifies for Free Shipping
    Available for Pre-Order. This item will be released on August 26, 2024
  • PICK UP IN STORE

    Store Pickup available after publication date.

Related collections and offers


Overview

This book provides a practical introduction to unconditional approaches to planning randomised clinical trials, particularly aimed at drug development in the pharmaceutical industry. This book is aimed at providing guidance to practitioners in using average power, assurance and related concepts.

Product Details

ISBN-13: 9781032111315
Publisher: CRC Press
Publication date: 08/26/2024
Series: Chapman & Hall/CRC Biostatistics Series
Pages: 212
Product dimensions: 6.12(w) x 9.19(h) x (d)

About the Author

Andrew P. Grieve is a Statistical Research Fellow in the Centre of Excellence in Statistical Innovation at UCB Pharma. He is a former Chair of PSI (Statisticians in the Pharmaceutical Industry) and a past-President of the Royal Statistical Society. He has over 45 years of experience as a biostatistician working in the pharmaceutical industry and academia and has been active in most areas of pharmaceutical R&D in which statistical methods and statisticians are intimately involved, including drug discovery, pre-clinical toxicology, pharmaceutical development, pharmacokinetics and pharmacodynamics, phase I-IV of clinical development, manufacturing, health economics and clinical operations.

Table of Contents

List of Figures..........................................................................................................xi

List of Tables......................................................................................................... xiii

Preface......................................................................................................................xv

Acknowledgements..............................................................................................xix

Author.....................................................................................................................xxi

List of Acronyms................................................................................................ xxiii

1. Introduction......................................................................................................1

2. All Power Is Conditional Unless It’s Absolute..........................................9

3. Assurance........................................................................................................33

4. Average Power in Non-Normal Settings...................................................59

5. Bayesian Power..............................................................................................75

6. Prior Distributions of Power and Sample Size........................................87

7. Interim Predictions......................................................................................101

8. Case Studies in Simulation........................................................................ 113

9. Decision Criteria in Proof-of-Concept Trials..........................................127

10. Surety and Assurance in Estimation........................................................149

References.............................................................................................................161

Appendix 1 Evaluation of a Double Normal Integral...................................171

Appendix 2 Besag’s Candidate Formula.........................................................173

Index......................................................................................................................175

From the B&N Reads Blog

Customer Reviews